Skip to content

Parametric Mapping in Paediatric Magnetic Resonance Imaging

Parametric Mapping in Paediatric Magnetic Resonance Imaging

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04068987
Enrollment
250
Registered
2019-08-28
Start date
2019-08-23
Completion date
2022-12-01
Last updated
2020-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Disease, Cardiomyopathies, Congenital Disorders, Pediatric Disease

Keywords

magnetic resonance imaging, parametric mapping

Brief summary

Magnetic resonance imaging (MRI) is increasingly an important tool for diagnosis and management of cardiac diseases in children. One of the uses of MRI is tissue characterisation, in which the signal characteristics of the cardiac muscle (myocardium) can be determined with special techniques, known as parametric mapping. There is increasing evidence that parametric mapping may be able to identify regions of scarring in the myocardium, or detection of oedema/inflammation in the setting. This in turn can help predict disease course and add value to the management of patients. There is also evidence that other structures that are visualised in parametric mapping aside from the heart (e.g. liver and spleen) can also help improve diagnostic accuracy and guide management. Currently the majority of studies describing the use of parametric mapping is focused on adults, with limited data on its use in children. The parametric mapping values can also differ amongst different machines, so calibration with normal subjects are also required.

Detailed description

Magnetic resonance Imaging (MRI) can provide tissue characterisation without radiation and need for invasive biopsy. Parametric mapping techniques (T1 mapping, extracellular volume fraction, T2 mapping, T2\* mapping) are methods of quantitative analysis of tissue properties, and are currently commercially available. T1 mapping, extracellular volume fraction (ECV) and T2\* mapping provides knowledge about the tissue properties of the myocardium, interstitium and adjacent structures,and can provide information for diagnosis of fibrosis, inflammatory and infiltrative diseases. T2 mapping is useful for assessing oedema, which may be useful in monitoring disease activity such as myocarditis. Parametric mapping has proven clinical utility in iron deposition, amyloid disease, Anderson-Fabry disease and myocarditis. In addition to assessment of cardiac muscle, tissue characterisation can also be performed in adjacent organs that are included in the field of view of parametric mapping (e.g. liver and spleen). Parametric mapping may provide important diagnostic information for decision making, patient monitoring and management planning. The investigators aim to 1. recruit healthy volunteers as controls to establish normal local reference ranges for parametric mapping values 2. recruit patients undergoing clinically indicated cardiac MRI to perform parametric mapping, and compare the parametric mapping values between normal controls and patients.

Interventions

DIAGNOSTIC_TESTMRI parametric mapping

Magnetic resonance (MR) sequences (T1 mapping, T2 mapping, T2\* mapping, ECV mapping) to determine the MR signal characteristics of the body

Sponsors

Hong Kong Children's Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
No minimum to 18 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy volunteers * Paediatric patients \<=18 years of age with suspected or confirmed cardiac disease undergoing clinically indicated MRI

Exclusion criteria

* Unstable or uncooperative patients that cannot tolerate MRI * Patients with contraindications for MRI (e.g. patients with implanted devices that are not MRI compatible)

Design outcomes

Primary

MeasureTime frameDescription
Parametric mapping values of normal subjects and patientsthrough study completion, up to 2 yearsParametric mapping values are generated upon completion of the MR sequence

Countries

Hong Kong

Contacts

Primary ContactKenneth Cheung, MBBS
cky630a@ha.org.hk+852 35136084
Backup ContactKenneth Cheung, MBBS
knnth.c@gmail.com+852 91516753

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026